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Hematopoiesis: From Beneficial to 
Detrimental effects on Bone Marrow 
Output
Maria Fernanda Pascutti†, Martje N. Erkelens†‡ and Martijn A. Nolte*
Landsteiner Laboratory, Department of Hematopoiesis, Sanquin, Academic Medical Centre, University of Amsterdam, 
Amsterdam, Netherlands
The ability of the bone marrow (BM) to generate copious amounts of blood cells 
required on a daily basis depends on a highly orchestrated process of proliferation and 
differentiation of hematopoietic stem and progenitor cells (HSPCs). This process can 
be rapidly adapted under stress conditions, such as infections, to meet the specific 
cellular needs of the immune response and the ensuing physiological changes. This 
requires a tight regulation in order to prevent either hematopoietic failure or transfor-
mation. Although adaptation to bacterial infections or systemic inflammation has been 
studied and reviewed in depth, specific alterations of hematopoiesis to viral infections 
have received less attention so far. Viruses constantly pose a significant health risk and 
demand an adequate, balanced response from our immune system, which also affects 
the BM. In fact, both the virus itself and the ensuing immune response can have a 
tremendous impact on the hematopoietic process. On one hand, this can be beneficial: 
it helps to boost the cellular response of the body to resolve the viral infection. But on the 
other hand, when the virus and the resulting antiviral response persist, the inflammatory 
feedback to the hematopoietic system will become chronic, which can be detrimental 
for a balanced BM output. Chronic viral infections frequently have clinical manifestations 
at the level of blood cell formation, and we summarize which viruses can lead to BM 
pathologies, like aplastic anemia, pancytopenia, hemophagocytic lymphohistiocytosis, 
lymphoproliferative disorders, and malignancies. Regarding the underlying mechanisms, 
we address specific effects of acute and chronic viral infections on blood cell produc-
tion. As such, we distinguish four different levels in which this can occur: (1) direct viral 
infection of HSPCs, (2) viral recognition by HSPCs, (3) indirect effects on HSPCs by 
inflammatory mediators, and (4) the role of the BM microenvironment on hematopoiesis 
upon virus infection. In conclusion, this review provides a comprehensive overview on 
how viral infections can affect the formation of new blood cells, aiming to advance our 
understanding of the underlying cellular and molecular mechanisms to improve the 
treatment of BM failure in patients.
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iNTRODUCTiON
All blood cells develop from a small subset of the same pro-
genitor cells in the bone marrow (BM) through a process called 
hematopoiesis. Hematopoietic stem cells (HSCs) give rise to 
red and white blood cells and platelets, and this hematopoietic 
process is tightly regulated to ensure both a balanced output 
of the different blood cells and a lifelong maintenance of self-
renewing HSCs (1). The contribution of individual HSCs to 
blood cell production under steady state conditions is low, as 
this is mainly governed by multipotent progenitors with less or 
no self-renewing capacity (2). HSCs only occasionally give rise 
to new progenitors and are instead protected and nurtured by 
a complex microenvironment of resident hematopoietic and 
non-hematopoietic cells (3). This BM niche produces factors 
that maintain the quiescence, self-renewal, and survival of the 
HSCs. However, upon stress induced by cytotoxic damage, 
transplantation, inflammation, or infection, the pool of quies-
cent HSCs is activated and required to actively contribute to the 
hematopoietic process (4).
Several types of immune cells and inflammatory cytokines are 
involved in the skewing of hematopoiesis by bacterial infections 
or sterile inflammation (4, 5). The hematopoietic response to 
acute systemic bacterial infection, often referred to as “emer-
gency granulopoiesis,” is characterized by systemic signs such 
as blood leukocytosis, neutrophilia, the emergence of immature 
neutrophils (clinically called left-shift), and increased production 
of myelomonocytic cells in BM (6). While the beneficial effect 
for the host to increase myeloid output to fight off a bacterial 
infection is evident, the desired BM output during a viral infec-
tion can be more complex. In this review, we give an overview 
of the impact of viral infections on hematopoiesis, and how the 
molecular feedback to the BM can contribute to improved viral 
clearance but also to either benign or malignant hematological 
disorders.
Viruses are small obligate intracellular parasites that require 
host cellular machinery for replication. That much said, there 
is an enormous variety of viruses, even of medically relevant 
viruses. Viruses that can infect humans range in size from 20 to 
260 nm, are estimated to be of at least 30 different types and can 
cause pathologies, ranging from respiratory manifestations, 
enterocolitis, meningitis, encephalitis, hepatitis, and sexually 
transmitted diseases. Structurally, viruses are composed of a 
protein capsid that protects their genomic material and, in 
some cases, facilitates entry into the host cell. Some viruses 
can also be surrounded by a lipid bilayer – enveloped viruses, 
which also contain membrane glycoproteins that can interact 
with entry receptors on the surface of the host cells. The genome 
of viruses can be composed of DNA or RNA. RNA genomes 
can be coding, much like an mRNA molecule (positive-strand 
RNA) or have a complementary RNA molecule (negative-
strand) that needs to be copied into a positive strand, which 
can then be translated by the cellular machinery. DNA viruses 
can have a single-stranded or double-stranded genome. The 
conformation of the genome can be linear or circular, and 
continuous or segmented. RNA genomes are limited by the 
inherent instability of RNA and usually contain fewer genes, 
with the smallest virus containing 3–4 genes. DNA genomes 
are generally bigger and might encode up to 200 genes. The 
size of the genome will impact the dependence of the virus 
on the cellular replication machinery and will also impact on 
how good the virus is in escaping immune responses. Bigger 
genomes are able to encode a broader range of sophisticated 
immune-evasion mechanisms (7).
A typical viral life cycle involves entry of the virus into 
the host cell, translation of viral proteins, replication of viral 
genome, assembly of viral particles, and final release of the 
mature virions into the extracellular milieu. All viruses have on 
their outside a receptor-binding protein. The receptors on the 
target cells invariably have another function but viruses have co-
opted them for attachment to the cell. Once attached, the virus 
can enter the cell by fusion with the cell membrane, receptor-
mediated endocytosis, or non-clathrin-mediated endocytosis. 
Eventually, the viral genome is released into the cytoplasm 
where it will be translated and replicated or reach the nucleus 
of the cell. Viruses code for strong signals to promote viral gene 
expression and other signals to repress expression of cellular 
genes. The expression of groups of viral genes is often carried out 
in critically timed phases with intermediate early genes coding 
regulatory proteins, early genes for genome replication proteins, 
and late viral genes for structural proteins. Once the viruses are 
assembled, the next step is release from the cell. Lytic viruses are 
released on lysis and death of the host cell. Non-lytic enveloped 
viruses bud from the cell surface. Viral infections can be acute, 
quickly resolved, or chronic, with some remaining in the host 
for its lifetime (7).
Viral infections start with local invasion, for example of an 
epithelial or mucosal barrier. Once the virus manages to over-
come the early mechanical barriers, such as cilia, mucus, or skin 
integrity and infects a target cell, innate immune mechanisms 
come into play to contain the infection. As an example, during 
influenza virus infection, viral RNA present within infected cells 
is recognized by pathogen recognition receptors (PRRs), which 
leads to the secretion of type I interferons (IFNs), pro-inflam-
matory cytokines, eicosanoids, and chemokines. Type I IFNs 
stimulate the expression of hundreds of genes [IFN-stimulated 
genes (ISGs)] in neighboring cells, which induce an antiviral 
state. Pro-inflammatory cytokines and eicosanoids cause local 
and systemic inflammation, induce fever and anorexia, and 
instruct the adaptive immune response. Chemokines recruit 
additional immune cells, including neutrophils, monocytes, and 
natural killer cells to the airways. Virally infected epithelial cells 
become the target of NK cells. Monocytes and neutrophils help 
to clear infected dead cells, thus contributing to viral clearance 
(8). If the virus establishes infection despite these defenses, the 
ultimate clearance of the virus requires adaptive immunity, 
which relies on virus-specific antibodies and T cells. As an 
example, T cell responses against influenza comprise perforin/
granzyme-induced lysis and tumor necrosis factor receptor 
family dependent apoptosis of infected cells and production of 
pro-inflammatory and regulatory mediators, such as IFNγ (9). 
In some cases, a strong antiviral response can even be more 
destructive than the virus itself and contribute to viral persis-
tence (10–12).
TaBle 1 | BM pathologies associated with human viral infections.
Pathology virus Comments Reference
Pancytopenia EBV Self-resolving (20)
HCV Afffected by medication (21)
Aplastic anemia Parvovirus 
B19







Driven by a strong antiviral 
T cell response and ensuing 
cytokine production
(24, 25)
Dengue Mechanism unknown (26)
HLH CMV Driven by the ensuing antiviral 












EBV Infectious mononucleosis and 
chronic active EBV disease
(20)




In this table, we summarize the viruses that can contribute to particular type of 
pathology in human BM.
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aDaPTaTiON OF HeMaTOPOieSiS TO 
iNFeCTiONS
Stress-induced hematopoiesis has most likely evolved to provide 
the body with the appropriate type(s) of blood cells to combat 
the invading pathogen. Signals originating from the infectious 
agent or the ensuing immune response can compel HSCs to 
change from a quiescent into a proliferative state and dictate the 
differentiation pathways of hematopoietic progenitors (13). For 
example, inflammation induced by immunization or LPS injec-
tion increases the production of granulocytes, macrophages, 
and dendritic cells but decreases the production of B cells 
(14, 15). Interestingly, the response of the hematopoietic system 
to bacterial products can also be influenced by non-immune cells, 
as BM stromal cells and endothelial cells can translate patho-
genic information to lineage-specific differentiation through 
the production of pro-inflammatory cytokines or chemokines 
(16, 17). Macrophages also play an important role in the BM in 
regulating myelopoiesis, both during the steady state and upon 
inflammation, as was reviewed by McCabe and MacNamara 
(18). Inflammatory mediators, such as interferon-γ (IFNγ), skew 
the differentiation of hematopoietic stem and progenitor cells 
(HSPCs) toward monocytes at the expense of other lineages, as 
we reviewed previously (19). Boosting myelopoiesis during infec-
tions while inhibiting other lineages is probably related to the fact 
that myeloid cells are short lived, have little ability to expand in 
the periphery, and are rapidly consumed during acute bacterial 
infections. However, monocytes and granulocytes are not essen-
tial for the clearance of a viral infection, whereas lymphocytic 
cells, such as NK cells and T cells do have an important role in 
the immune response against viruses. Therefore, it is conceivable 
that significant differences exist in hematopoietic output upon an 
infection with a bacterial versus viral pathogen. In the coming 
section, we will discuss non-pathogenic and pathogenic outcomes 
of viral infections on BM output, and then, we will elaborate on 
four distinct effects by which viral infections can modulate the 
hematopoietic process.
PaTHOGeNiC OUTCOMe OF  
viRal iNFeCTiONS
Numerous viral infections have been associated with BM failure 
or hyperproliferative syndromes. A summary of BM pathologies 
associated with human viral infections is outlined in Table 1, and 
a short description of terms and examples follows.
Pancytopenia is a deficiency of all three blood cell types: red 
blood cells (anemia), white blood cells (leukopenia), and platelets 
(thrombocytopenia). In rare cases, it can appear as a direct self-
resolving consequence of viral infection, such as that observed 
during EBV-associated infectious mononucleosis (20), but in 
most cases, it is secondary to other hematological disorders, 
such as aplastic anemia or hemophagocytic lymphohistiocytosis 
(HLH). HCV-infected patients are also prone to developing 
peripheral cytopenias, which has been proposed to be a multi-
factorial process also influenced by antiviral medication, such as 
Ribavirin (21).
Aplastic anemia is a BM failure condition where the BM 
contains very few hematopoietic cells and consists mainly of 
fat. Because of defective hematopoiesis, aplastic anemia results 
in pancytopenia. Viral infections associated with aplastic 
anemia include parvovirus B19 (22, 23), Epstein–Barr virus 
(EBV), cytomegalovirus (CMV), varicella-zoster virus (VZV), 
human herpes virus 6 (HHV-6), human immunodeficiency 
virus (HIV), hepatitis A and C viruses (HAV and HCV), and 
dengue (21, 24). Parvovirus B19 is highly tropic to human BM 
and replicates only in erythroid progenitor cells. In individuals 
with underlying hemolytic disorders, infection with parvovirus 
B19 is the primary cause of transient aplastic crisis. In immuno-
compromised patients, persistent B19 infection may develop and 
lead to pure red cell aplasia and chronic anemia (22). It has been 
proposed that, in most acquired cases, the hematopoietic tissue 
is the target of oligoclonal CD8+ T cells, which secrete IFNγ and 
TNFα and cause hematopoietic cell death (19, 25). Alternatively, 
continuous production of these pro-inflammatory cytokines can 
also exhaust the HSC compartment and thereby lead to aplastic 
anemia (5, 19, 33).
Hemophagocytic lymphohistiocytosis is a rare hyperinflamma-
tory syndrome that is characterized by an uncontrolled activa-
tion of macrophages and lymphocytes and a life-threatening 
cytokine storm, accompanied by pancytopenia, among other 
complications. Primary HLH is caused by mutations in genes 
that regulate granule-dependent cytotoxicity of cytotoxic T cells 
and NK cells. Secondary HLH has infectious and non-infectious 
triggers. Among the infectious triggers, viral infection is the 
most frequent, either as a primary infection in healthy people or 
after reactivation in immunosuppressed patients. Herpes viruses, 
such as EBV and CMV account for 62% of reported viral cases 
of HLH in adults (34). Five murine models of genetic HLH have 
been established to study the pathogenesis of HLH. All of them 
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display the same disease manifestations as humans and require 
a viral trigger to develop HLH (35). Murine CMV infection 
models have highlighted that pathologic mechanisms may be 
different in primary and secondary HLH (27). Pathogenesis 
of primary HLH is associated to hyper-activated CD8+ T cells, 
producing large amounts of IFNγ (28), while CD8+ T cells 
seemed dispensable, and IFNγ had more of a regulatory than 
a pathogenic role during secondary HLH (27). Other viruses, 
such as Dengue, have also been associated to this pathology 
(29, 30), although causative relationships are still missing. All in 
all, the systemic and BM-associated pathology, i.e., pancytope-
nia, in HLH seem to arise due to excessive inflammation, not by 
direct effect of the viral infections. However, the question remains 
as to why certain viruses can trigger such excessive responses and 
to what extent this is related to the genetic or immunological 
makeup of the host.
Finally, some viral infections, such as EBV, may lead to lym-
phoproliferative disorders and/or lymphoid malignancies. EBV-
driven B cell lymphoproliferative disorders have been extensively 
studied and arise from latently infected B cells. Of all the different 
manifestations, which can affect different lymphoid organs and 
peripheral tissues, BM involvement has been described dur-
ing infectious mononucleosis and chronic active EBV disease. 
Reported BM involvement included pancytopenia, as mentioned 
before, and detection of proliferating transformed cells (20). 
Patients with HCV infection develop a number of hematologic 
disorders, with benign and malignant B cell proliferations being 
the most common (21). HCV can infect, but not replicate, in B 
cells, and B cell proliferation in HCV-infected patients seems 
to result from chronic antigenic stimulation (21). All in all, BM 
involvement associated with lymphoproliferative disorders and 
malignancies seem to arise through, yet uncharacterized, indirect 
mechanisms and not by direct transformation of HSPCs.
In general, most reports regarding the effect of viral infections 
on BM output refer to pathologic conditions where hematopoiesis 
is seriously perturbed. It is likely that many acute viral infections 
induce transient alterations on the hematopoietic process, through 
the action of mediators such as type I IFNs, TNF, and lympho-
toxin (LT), as has been described in mice models of lymphocytic 
choriomeningitis virus (LCMV) (36) and Influenza infections 
(37). In the case of LCMV, transient BM aplasia is dependent on 
type I IFNs (36). In influenza-infected mice, B cell precursors 
transiently decreased in numbers in a TNF- and LT-dependent 
manner (37). These effects are most likely overlooked in many 
human acute viral infections because of their subclinical nature.
Although the particular pathogenic mechanisms underlying 
all these BM manifestations are not fully understood, two obser-
vations seem to stand out from the data. First, many different 
viruses give rise to the same pathological outcome, which sug-
gests that common underlying mechanisms either of virological 
or immunological origin might be responsible, and indeed, 
the immune response plays a major role in the pathogenesis of 
aplastic anemia and pancytopenia. Second, the fact that a certain 
virus can lead to different pathological manifestations in differ-
ent individuals points to a genetic basis for aberrant immune 
activation in BM failure, as suggested before (19, 25). In general, 
mechanistic studies in animal models are scarce. Dissection 
of common and pathogen-specific mechanisms could greatly 
improve therapy and management of affected patients.
As a general conclusion, many types of viruses can affect 
hematopoiesis and, in this section, we have described examples 
of acute (Parvovirus B19, dengue) and chronic (CMV, HIV), 
systemic (HIV), and localized (Influenza) infections, which 
directly or indirectly, transiently or more permanently, affect 
the hematopoietic process. In the following sections, we will 
elaborate on well characterized and also proposed mechanisms 
behind these processes.
MeCHaNiSMS OF viRal iNTeRFeReNCe 
wiTH HeMaTOPOieSiS
Both viruses and immune responses directed toward them have 
an impact on hematopoiesis. In an elegant review, King and 
Goodell previously categorized four different mechanisms by 
which infections in general can influence HSC biology (4). The 
first two mechanisms act via direct effects on HSCs: (1) direct 
infection or (2) direct recognition of a pathogen. The other 
two mechanisms are indirect: (3) either via pro-inflammatory 
cytokines released by other cells or (4) through changes in the 
BM microenvironment. These four scenarios are not mutually 
exclusive and can even enhance or attenuate each other. In the 
coming sections, we will use this subdivision to describe how 
viral infections can affect BM output in general and the function 
of HSPCs in particular (Figure 1).
Direct viral infection of HSPCs
It has been described that a number of viruses including, CMV, 
Hepatitis C virus (HCV), and human herpes viruses can directly 
infect HSPCs (38–41). For some of these viruses, it has been 
documented that they can suppress hematopoiesis after direct 
infection of HSPCs. For example, Simmons et al. demonstrated 
that CMV infection can mediate myelosuppression in vitro (42). 
Furthermore, human herpes viruses 7 (HHV7) has the potential 
to infect HSPCs as well as impair HSPC survival and proliferation, 
presumably via lysis, or induced cell death (41). Parvovirus B19, 
the only known human pathogenic parvovirus, has a selective 
tropism for the erythroid lineage in the BM, where productive 
infection induces a block in erythropoiesis that can be manifested 
as a transient or persistent erythroid aplasia (43).
Moreover, the consequence of direct viral infection of 
HSPCs, such as changes in the expression of intracellular 
factors e.g., microRNAs, may impact hematopoiesis as well. 
It was shown that retroviruses such as HIV and HTLV target 
microRNAs to manipulate key cellular pathways, which can 
result in the development of hematopoietic malignancies such 
as B cell and Hodgkin’s lymphomas (44, 45). Furthermore, it was 
observed that both HIV and SIV can induce large hematopoietic 
defects. Prost et al. demonstrated that the inhibitory effects on 
hematopoiesis of SIV depend entirely on the presence of the 
viral protein Nef. They showed that SIV affected HSPCs by 
downregulating STAT5a and STAT5b via Nef in vivo and dem-
onstrated that SIV strongly downregulates early hematopoiesis 
in this manner (46).
FiGURe 1 | Graphical representation of four different mechanisms by which viral infections can influence the function of HSPCs. The first two 
mechanisms act via direct effects on HSPCs: (1) direct viral infection or (2) viral recognition by HSPCs. The other two mechanisms are indirectly: (3) via inflammatory 
mediators or (4) through changes in the BM microenvironment. During a viral infection, more than one of these mechanisms contribute to alterations in 
hematopoiesis, as they are also likely to influence each other, as indicated by the gray arrows. This is exemplified by the fact that (a) when a virus infects an HSPC, 
it is generally also recognized through intracellular PRRs, (B) recognition of viral infections by HSPCs usually also leads to the production of pro-inflammatory 
cytokines, such as type I IFNs, and (C) production of IFNγ by virus-specific T cells can directly affect HSPCs but can also induce IL-6 production by MSCs, thereby 
enhancing myeloid differentiation. Better understanding of the complex interactions between these different mechanisms will be important to adequately treat or 
prevent anemia and BM failure in patients with viral infections. (The illustrations used to generate this figure are gratefully obtained from the Powerpoint Image Bank 
of Servier Medical Art).
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Overall, direct viral infection in HSPCs has been shown to 
reduce the hematopoietic output. However, the exact underlying 
mechanisms after direct virus infections in HSPCs have not been 
fully elucidated. It is conceivable that the halt of translation in 
host cells (or “shut off ”) that occurs in many cells following viral 
infection contributes to this process, though the impact of this 
antiviral mechanism on HSPC function is not clear.
It has been proposed that direct infection of HSCs does not 
commonly occur, as they usually reside in protected BM niches 
(4). Because of this protected microenvironment, quiescent 
HSCs are thought to be resistant against bacterial infections (47). 
In fact, all the evidence described in the preceding paragraphs 
does not distinguish between infection of HSCs or downstream 
progenitors. It remains to be determined whether there are any 
differences in virus susceptibility between these cell types. It is 
likely that quiescent HSCs are less likely to become infected with a 
virus compared to their non-quiescent counterparts, and evidence 
supporting this notion is described in the following section.
Role of Direct Recognition of viral PaMPs 
in Stress-induced Hematopoiesis
Pathogen recognition receptors are receptors that detect path-
ogen-associated molecular patterns (PAMPs) within the body 
(48, 49). PRRs include toll-like receptors, retinoic acid-inducible 
gene 1 (RIG-I)-like receptors (RLRs), and cyclic guanosine 
monophosphate-adenosine monophosphate (cGAMP) synthase 
(cGAS) (50). Four TLR members seem to play a critical role 
in recognition of viral nucleic acids: TLR3 recognizes dsRNA 
(dsRNA constitutes the genome of one class of viruses but is 
also generated during the life cycle of many viruses), TLR7 and 
8 recognize single-stranded RNA (ssRNA), and TLR9 responds 
to dsDNA viruses recognizing non-methylated viral CpG-
containing DNA. Although the majority of TLRs sense pathogen 
components on the cell surface, TLR3, TLR7, TLR8, and TLR9 
sense nucleic acids in endosomal compartments. Other TLRs are 
also involved in viral recognition; TLR2 and TLR4 were shown to 
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detect viral components such as envelope glycoproteins (51) and 
other components of viruses such as HIV, HBV, vaccinia virus 
(VV), and Dengue (52–55).
Interestingly, several intracellular and extracellular TLRs have 
been found on HSCs (13). It was shown both in vitro and in vivo that 
direct TLR ligation triggered cell cycle entry in quiescent HSCs, 
bringing them into a proliferative state (14, 56, 57). This indicates 
an active role for HSCs in immune sensing, and the modulation 
of early hematopoiesis during infection. De Luca et al. reported 
that human HSCs and lineage-committed progenitors express 
TLR3 (58), whereas Sioud et al. showed that HSPCs particularly 
express TLR7 and TLR8 (57). These different observations could 
be explained by different sources of cells that were used, as De 
Luca et al. isolated HSPCs from cord blood, whereas Sioud et al. 
isolated these cells from BM of healthy donors. Although side-
by-side validation is lacking, differential TLR expression in fetal 
vs. adult HSCs suggests that these cells may be equipped to detect 
and respond to different viral infections. Furthermore, HSPCs 
also express TLR2 (14, 59). Finally, exposure of murine HSPCs to 
TLR ligands has also been shown to modulate their chemokine 
receptor expression (6) suggesting that TLR triggering may even 
regulate their migratory and homing capacities. In line with this, 
a comparison of TLR expression patterns between BM resident 
and mobilized HSPC could reveal interesting differences as to 
their response to viral infection in terms of lineage commitment 
and adaptation to demand. It might be that mobilized HSPCs in 
tissues have an increased surveillance capacity than those in the 
BM, but this remains to be demonstrated.
While signaling through TLR7 and TLR8 resulted in HSPC 
differentiation along the myeloid lineage (57), in the presence 
of ligands for TLR9, the in  vitro generation of DCs dramati-
cally decreased in favor of the production of macrophages (60). 
Correspondingly, it was demonstrated that the potential of 
myeloid progenitors to produce DCs was reduced upon TLR9 
ligation (61). However, lymphoid progenitors from mice with 
a herpes virus infection were biased toward DC differentiation, 
which was dependent on TLR9, and that treatment of uninfected 
mice with the TLR9 ligand CpG ODN resulted in an increased 
DC generation (61). These findings indicate that TLR9 trigger-
ing differentially affects the generation of myeloid vs. lymphoid 
lineage-derived DCs. Furthermore, in the setting of acute 
leukemia, Dorantes-Acosta et  al. found that leukemic HSPCs 
respond differently to various TLR ligands (62). Their findings 
suggested that B cell development is only marginally influenced 
by infectious agents, whereas they observed an increased produc-
tion of myeloid and NK cell types in response to infections and 
disease-associated cell damage. For example, they observed an 
increase in the development of mature CD56+CD11c+ NK cells 
after stimulation of TLR8 and TLR9 in chronic acute leukemia-
derived BM cells (62).
Besides affecting lineage commitment, viral sensing might also 
directly affect HSPC survival. Ligation of the RLRs RIG-I/MDA-
5, but not TRL3, by poly I:C triggered apoptosis of human CD34+ 
cells, through a type I IFN-independent, caspase-dependent 
mechanism (63). It has, in fact, been shown that RLRs can trigger 
a dual response in virus-infected cells, which are independent 
and both contribute to viral control (64, 65). RLR-signaling 
activates IRF-3, which then migrates to the nucleus and binds to 
the IFN-stimulated response elements (ISRE) in the promoters of 
the target genes to induce type I IFN expression (64). In parallel, 
IRF3 can also activate the RLR-induced IRF-3-mediated pathway 
of apoptosis (RIPA) (65). It has long been reported that not every 
infected cell produces type I IFN (66, 67); there is heterogeneity 
in the type I IFN production within populations of virus-infected 
cells, which may be linked to expression levels of RIG-I signaling 
components or heterogeneous chromatin status of IFNβ genomic 
locus (67). It might be that the quiescent HSCs respond differ-
ently to RLR triggering than downstream progenitors. It is to be 
expected, given the relevance of maintaining the HSC pool for 
life, that quiescent HSC are more prone to inducing type I IFN 
production, which is followed by activation of numerous antiviral 
mechanisms, instead of inducing the RIPA pathway that kills the 
cells. There is potentially less biological cost in inducing RIPA 
in multipotent progenitors to limit viral replication, because 
these cells can be replaced by long-term HSCs later on. In line 
with this, a comprehensive proteomics analysis (68) revealed 
differences between HSPCs (Lineage-Sca-1+c-kit+ cells) and 
myeloid progenitors (Lineage −Sca-1−c-kit+ cells). Strikingly, 2 
′–5′ oligoadenylate synthetase 3 (Oas3), RIG-I, and Ifit1, three 
different cytoplasmic sensors for viral RNA, were strongly 
upregulated in the multipotent state as well as a number of anti-
viral interferon-stimulated proteins. These results suggest that, 
compared to downstream progenitors, HSPCs might actually be 
more prone to activating the IFN antiviral response, although 
differences between quiescent HSC and multipotent progenitors 
remain to be shown. In fact, HSPCs are poorly permissive to both 
retroviral- and lentiviral-based gene transfer. Lentivirus has the 
advantage that they do not require cycling cells to integrate their 
genome and could potentially be more suitable for transforma-
tion of quiescent HSCs. Nevertheless, genetic manipulation of 
HSPCs still requires the use of multiple hits of high vector doses 
and prolonged ex vivo culture, suggesting that permissiveness is 
not only dependent on cell-cycle but also on the activation of 
multiple innate immune sensors and restriction factors that limit 
viral infection (69).
Altogether, it is clear that HSPCs can respond to viral infec-
tions through direct recognition of several viral PAMPs, and that 
the activation of different PRRs can result in different biological 
outcomes, ranging from changes in chemokine receptor expres-
sion and lineage-specification to induction of apoptosis.
indirect effects of viral PRR  
Triggering on Hematopoiesis
In response to PRR ligation by viruses, immune and non-
immune cells produce a number of cytokines and chemokines. 
These include IL-1β, IL-6, IL-8, IL-10, TNFα, GM-CSF, TGFβ, 
CCL3 (MIP-1α), CCL4 (MIP-1β), CXCL10 (IP-10), and type I 
IFNs. Different viruses induce slightly different patterns that 
depend on the interaction of the particular viral PAMP with 
the specific PRR and the cell type involved (70, 71). In general, 
pro-inflammatory cytokines like IL-1β, IL-6, and TNFα together 
with type I IFN production are common to all viral, and many 
bacterial, infections (70). Many viruses that persist, such as EBV, 
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HIV, and HTLV-I, signal innate cells such as dendritic cells, NK 
cells, and macrophages to produce anti-inflammatory molecules 
such as IL-10 and TGFβ (70, 71).
High levels of IFNα directly induces HSCs to exit quiescence 
and transiently proliferate in vivo (72, 73). Since most cell types 
stop proliferating in response to IFNα, the wiring of this signaling 
pathway must be fundamentally different in HSCs (74). According 
to Pietras et  al. (75), type I IFN-driven HSC proliferation is a 
transient event resulting from a brief relaxation of quiescence-
enforcing mechanisms in response to acute type I IFN exposure, 
which occurs exclusively in vivo. This proliferative burst fails to 
exhaust the HSC pool, which rapidly returns to quiescence in 
response to chronic type I IFN exposure, achieved by repeated 
polyI:C administration, because of the presence of intrinsic 
regulatory mechanisms. Type I IFN-exposed HSCs with re-
established quiescence are not fully functional but are also largely 
protected from the killing effects of IFNs unless forced back into 
the cell cycle due to culture, transplantation, or myeloablative 
treatment, at which point they activate a p53-dependent proa-
poptotic gene program (75). These ideas are further supported 
by independent findings showing that, when genes that normally 
suppress IFN signaling are disrupted, mice have increased levels 
of IFN signaling, and their HSC populations are depleted over 
time (73, 76, 77). In chimeric mice transplanted with both wild-
type HSCs and IFNα-receptor-deficient (IFNαR−/−) HSCs and 
later exposed to IFNα, only the IFNαR −/− HSCs survived (72). In 
fact, exit from quiescence, induced by polyI:C or other stimuli, 
leads to generation of DNA damage that activates a DNA dam-
age response in HSCs. Repeated activation of HSCs out of their 
dormant state provoked their attrition, and this was exacerbated 
in mice with a defect in DNA repair, suggesting that inefficient 
repair of replicative DNA damage may result in HSC depletion 
(78). Additionally, one single dose of IFNα or polyI:C induced 
an increase in the production of megakaryocyte-related proteins 
by acting on a stem-cell-like megakaryocyte progenitor that is 
contained within the phenotypically characterized HSC pool. 
Again, chronic exposure to polyI:C triggered exhaustion of these 
stem-cell-like megakaryocyte progenitors and a delayed repletion 
of platelet counts (79). Recent work also proposes that chronic 
exposure to IFNα drives medullar lymphopoiesis toward T-cell 
differentiation, while impairing the generation of B, NK, myeloid 
cells, erythrocytes, and platelets (80). Collectively, these findings 
suggest that BM aplasia associated with chronic exposure to 
type I IFN could arise from a depletion or loss of function of 
progenitors, together with enforced quiescence of HSCs, which 
become less functional. Moreover, if subsequent inflammation or 
infections force these quiescent HSC chronically exposed to type 
I IFNs back into cell cycle or if control mechanisms such as those 
regulating IFN signaling or DNA damage repair are deficient in 
certain susceptible individuals, this might lead to rapid depletion 
of the HSC quiescent pool and ensuing BM failure.
After the first wave of type I IFNs produced by infected cells, 
type II IFN (IFNγ), produced by stimulated T cells and NK cells, 
also contributes to the impairment of HSC self-renewal (81, 82). 
IFNγ triggering on HSPCs enhances monocyte formation, but 
this is at the expense of the production of neutrophilic (83) and 
eosinophilic granulocytes (84), B cells (85, 86), and erythrocytes 
(87, 88). These data illustrate that IFNγ has a wide-ranging effect 
on the hematopoietic process in the BM (19). It seems clear that 
type I and type II IFNs have unique features, with type I IFNs 
leading to megakaryopoiesis on the short term and quiescence 
and T-cell-biased lymphopoiesis upon chronic exposure, while 
IFNγ favors myelopoiesis at the expense of other branches of dif-
ferentiation. This might link the temporal expression of the two 
types of IFN to the changing needs of the immune response as it 
progresses from initial innate control to adaptive mechanisms.
As mentioned before, PRR stimulation by viruses can also 
lead to the production of pro-inflammatory cytokines and 
chemokines, which can in turn affect the proliferation and 
differentiation of HSCs. Several cytokines such as IL-1β, IL-6, 
TNFα, TGFβ, M-CSF, and GM-CSF have been identified to have 
the capacity of regulating the proliferation and differentiation of 
HSCs as reviewed by Mirantes et al. (33). Overall, these results 
indicate that cytokines can instruct the differentiation and pro-
liferation of HSCs, with BM output being a complex integration 
of signals from the microenvironment. As with prolonged type I 
IFN exposure, overproduction of inflammatory cytokines is often 
associated with hematopoietic failure such as chronic inflamma-
tory diseases and hematopoietic malignancies (33), but the indi-
vidual contribution of each player, and their potential synergies 
and antagonisms, remains to be determined. Finally, apart from 
inflammatory cytokines, costimulatory molecules may also play 
a significant role in altering hematopoiesis during viral infection 
(5). One example is the interaction between CD27 and CD70, 
which is important in the control of T cell immunity against 
Influenza (89) and CMV (90). This is of interest for the BM, as we 
previously showed that CD27-triggering on HSPCs may serve as 
a negative feedback mechanism that can regulate hematopoiesis 
during inflammatory conditions (91). This provides another layer 
of complexity by which immune activation can modulate the BM 
output upon viral infection.
Role of the BM Microenvironment on 
Hematopoiesis upon virus infection
As described for sterile inflammation and bacterial infections, 
viral infections may also affect hematopoieisis indirectly via the 
BM microenvironment. Apart from hematopoietic cells, the BM 
also contains non-hematopoietic components, such as osteoblasts, 
mesenchymal stromal cells (MSCs), adipocytes, perivascular 
cells, endothelial cells, and non-myelinating Schwann cells. It has 
long been recognized that non-hematopoietic stromal cells in the 
BM are capable of supporting long-term hematopoiesis in vivo, 
and that the integrity of several populations of cells is crucial for 
the long-term maintenance of the quiescent HSC pool (92, 93).
Infection of mice with different strains of LCMV leads to 
transient type-I IFN-dependent BM aplasia that reaches a 
minimal BM cellularity within 3 days and recovers within 10 days 
after infection, coinciding with viral clearance. Although the 
mechanisms have not been clearly dissected, LCMV can infect 
both stromal cells and megakaryocytic and myelocytic precur-
sors (36). It is likely that the aplasia is a result of apoptosis of 
the hematopoietic progenitors, which might be modulated by 
type I IFN signaling, as described above. However, the effects of 
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viral infection on the stromal cells have not been dissected. It 
would be very interesting to address whether these cells die from 
apoptosis or respond by secreting cytokines that can affect hemat-
opoiesis. If different populations of stromal cells are depleted 
and the hematopoietic niches are destroyed, the mechanisms by 
which these niches are reconstituted after viral clearance are still 
unknown. In this line, an important role for stromal cells in the 
hematopoietic stress-induced response during LCMV infection 
has been demonstrated by Schürch et al. (94). They described that 
IFNγ produced by CD8 T cells during the adaptive response to 
LCMV can also affect HSCs in an indirect manner by inducing 
IL-6 production in non-hematopoietic stromal cells (94), which 
in turn enhances myelopoiesis by downregulating the expres-
sion of Runx-1 and Cebpα in hematopoietic progenitor cells. 
Importantly, this increase in myelopoiesis was not only seen upon 
LCMV infection but also upon infection with vesicular stomatitis 
virus (VSV) or VV, suggesting that it is a general response to viral 
infection (94). These observations indicate that IFNγ not only 
acts directly on HSPCs, as described above, but also in an indirect 
manner via non-hematopoietic BM cells.
Mesenchymal stromal cells have also been reported to be 
affected by HIV, by a mechanism involving Tat and Nef (95). 
MSCs chronically treated with Tat and/or Nef reduced their 
proliferative activity, underwent early senescence, and showed 
decreased potential for osteoblastic differentiation, which could 
explain why HIV infected individuals present a higher prevalence 
of osteopenia/osteoporosis. Although no direct link was made, 
loss of the BM MSC functionality may have consequences on 
hematopoiesis.
Additionally, BM MSCs have been proposed to be a natural 
reservoir for human CMV (96). A recent retrospective study has 
shown that the CMV status of both donor and host are relevant 
for the overall survival of patients receiving allogeneic stem 
cell transplantation (HSCT) (97). As expected, CMV-negative 
recipients benefit from receiving HSCT from a CMV-negative 
donor, since the virus transmitted from a seropositive donor 
into an immunosuppressed seronegative recipient can have 
devastating effects. More intriguingly, CMV-positive recipients 
have an increased overall survival after receiving HSCT from a 
CMV-positive donor after myeloablative conditioning but not 
after reduced-intensity conditioning. Interestingly, there were 
differences in the causes of death between patients with CMV-
seropositive or CMV-seronegative donors. Patients who received 
grafts from CMV-seronegative donors were more likely to die 
from viral infection given as the only cause of death or where a 
viral pathogen was included as a part of a mixed infection with 
different organisms. This effect was abrogated by T-cell depletion 
(97), which suggests that memory T cells from the donor can help 
control viral infections in situations of more aggressive condition-
ing. Since recipient MSCs are not depleted during either of the 
conditioning regimes (98), and they can harbor CMV, it would be 
interesting to study the interaction between donor CMV-specific 
memory T cells and host CMV-infected stroma, and how this 
interaction is modulated by the conditioning treatment.
Another virus that has a significant impact on the BM micro-
environment in mice is the type B coxsackievirus (CVB). Althof 
et al. observed that after 3–4 days of infection, the femoral BM 
stroma was largely destroyed. While granulocyte and macrophage 
progenitors showed a relatively normal proliferative capacity, 
there was a marked decrease in colony-forming capacity in both 
erythroid and lymphoid progenitors, indicating a differential 
impact on the various HSPC subsets (99). Production of type I 
IFNs was shown to contribute to the development of lymphope-
nia upon CVB infection (99), which could also further contribute 
to the hematopoietic defects of the other hematopoietic lineages.
Although the contribution of the BM microenvironment to 
stress-hematopoiesis can be mediated through direct recognition 
of the pathogen and/or the ensuing production of inflammatory 
mediators, it may also simply be driven by the absence of particu-
lar cell types. Scumpia et al. observed that HSPC expansion upon 
bacterial infection can occur even without sensing of the bacte-
rial PAMPs (using MyD88 −/ −TRIF −/ − mice). They suggest that 
reduction in BM cellularity alone is sufficient to induce HSPC 
expansion, possibly mediated by supporting stromal cells that can 
provide the necessary signals for HSPC expansion within the BM 
space left void following infection or chemotherapeutic BM abla-
tion (100). Similarly, it has been suggested that granulopoiesis can 
be driven by the number of neutrophils present in the BM. At low 
neutrophil numbers, macrophages and DCs produce IL-23, which 
stimulates IL-17 production by T cells, which in turn increases 
granulopoiesis via G-CSF. On the other hand, at high neutrophil 
numbers, the production of IL-23 in DCs and macrophages is 
inhibited by the phagocytosis of apoptotic neutrophils, resulting 
in a negative feedback loop (101). Large numbers of neutrophils 
are predominantly important in fungal and bacterial infections, 
and whether similar interactions are at play in viral infections 
is currently unknown. However, it is an interesting concept that 
the sheer presence or absence of particular cell types in the BM 
can also contribute to the virally induced hematopoietic stress 
response.
Overall, the link between the BM microenvironment and 
hematopoiesis is not easy to define. Multiple pathways can play a 
role in the regulation of hematopoiesis via the BM microenviron-
ment, and these pathways may further complement each other. 
Yet, understanding the underlying cellular and molecular mecha-
nisms by which the BM responds to viral infections may help us 
to counteract the ensuing pathogenic consequences, which were 
discussed at the beginning of this review.
CONClUSiON aND FUTURe DiReCTiONS
Viral infections can cause direct and indirect damage to HSPCs 
and the surrounding tissue. Direct pathogenic effects depend 
on viral tropism and viral cycle, and there are a few examples 
of direct infection of HSPCs that lead to altered BM output, e.g., 
parvovirus B19. But the complex interactions between viruses, 
HSPCs, and the BM microenvironment are underappreciated 
at the moment. One such case is CMV, which can infect both 
stroma and HSPC, with the end result of chronic latent infection 
and no overt BM pathology. Acute viral infections usually cause 
transient aplasia, partly related to the effect of type I IFNs, and to 
direct viral infection, in which both HSPCs and stromal cells are 
depleted. The mechanisms involved in repopulation of the BM by 
HSCs are well known. However, very little is known about how 
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MSCs and other stromal cells recover from acute damage and 
by which mechanisms the different BM niches are reconstituted 
after resolution of infection. Insights into these processes could 
help understand BM repair in other situations, such as after radia-
tion or chemotherapy. This information has direct translatable 
potential into the clinic, as enhanced niche reconstitution could 
be highly beneficial after HSC transplantation. Finally, a link 
between direct viral infection of HSPCs and transformation has 
not been found. Instead, some hyperproliferative syndromes arise 
after infection of mature B cells, and BM involvement appears 
as a secondary condition. Indirect damage arising from acute 
or chronic viral infection has been frequently attributed to the 
antiviral immune response, with IFNγ and CD8+ T cells playing 
a major role. However, BM pathologies are rare events and often 
associated to alterations in gene regulation of cytokines, effector, 
and MHC molecules, which suggest a genetic basis for aberrant 
T cell activation in BM failure [reviewed in Ref. (19, 25)].
Furthermore, one final interesting aspect that deserves explor-
ing is the concept of the BM as a site of immune privilege. The BM 
contains a high proportion of regulatory T cells (Tregs), which 
have been proposed to protect the HSC niche (102). Although 
this concept was tested under conditions of allogeneic HSC trans-
plant, there are no examples of control of antiviral responses by 
BM Tregs. It would be very interesting to dissect how Tregs shape 
the interactions between viruses, HSPCs, and stroma, and how 
this affects viral clearance, skewing of hematopoiesis, and niche 
regeneration.
Overall, hematopoiesis is a very flexible process that quickly 
adapts to the needs of the host, providing an adjusted cellular 
output to fight off a certain pathogen. While considerable insight 
has been gathered regarding the regulation of BM output by 
general inflammatory processes and bacterial infections, less is 
known about the specific regulation of hematopoiesis by viral 
infections. Some of the previously described mechanisms also 
apply to this situation. Virus-specific T cells produce copious 
amounts of IFNγ and TNFα that in turn affect hematopoiesis; 
besides, chronic (latent or active) viral infections can induce 
chronic inflammation, associated with increased risk of develop-
ing BM pathology. Recognition of viral PAMPs by PRRs leads 
to the production of type I IFNs, with antiviral and immune 
stimulatory properties that are beneficial for viral clearance. 
Short-term effects of type I IFNs on hematopoiesis point toward 
temporary aplasia and potential skewing to megakaryopoiesis, 
but the long-term effects of type I IFN signaling on hemat-
opoiesis are still under debate and may be less deleterious than 
those described for IFNγ, due to the presence of regulatory 
mechanisms. Yet, our understanding of the full breadth by 
which viral infections affect hematopoiesis remains limited. It 
is thus important to further unravel the responsible cellular and 
molecular players in this process and their complex interplay in 
order to adequately treat or prevent anemia and BM failure in 
patients with viral infections.
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